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Abstract
Background: Accumulating evidence supports the role of the mineralocorticoid receptor (MR) in the pathogenesis
of diabetic nephropathy. These findings have generated renewed interest in novel MR antagonists with improved
selectivity against other nuclear hormone receptors and a potentially reduced risk of hyperkalemia. Characterization
of novel MR antagonists warrants establishing translatable biomarkers of activity at the MR receptor. We assessed
the translatability of urinary sodium to potassium ratio (Na
+/K
+) and plasma aldosterone as biomarkers of MR
antagonism using eplerenone (Inspra
®), a commercially available MR antagonist. Further we utilized these
biomarkers to demonstrate antagonism of MR by PF-03882845, a novel compound.
Methods: The effect of eplerenone and PF-03882845 on urinary Na
+/K
+ and plasma aldosterone were
characterized in Sprague-Dawley rats and spontaneously hypertensive rats (SHR). Additionally, the effect of
eplerenone on these biomarkers was determined in healthy volunteers. Drug exposure-response data were
modeled to evaluate the translatability of these biomarkers from rats to humans.
Results: In Sprague-Dawley rats, eplerenone elicited a rapid effect on urinary Na
+/K
+ yielding an EC50 that was
within 5-fold of the functional in vitro IC50. More importantly, the effect of eplerenone on urinary Na
+/K
+ in healthy
volunteers yielded an EC50 that was within 2-fold of the EC50 generated in Sprague-Dawley rats. Similarly, the
potency of PF-03882845 in elevating urinary Na
+/K
+ in Sprague-Dawley rats was within 3-fold of its in vitro
functional potency. The effect of MR antagonism on urinary Na
+/K
+ was not sustained chronically; thus we studied
the effect of the compounds on plasma aldosterone following chronic dosing in SHR. Modeling of drug exposure-
response data for both eplerenone and PF-03882845 yielded EC50 values that were within 2-fold of that estimated
from modeling of drug exposure with changes in urinary sodium and potassium excretion. Importantly, similar
unbound concentrations of eplerenone in humans and SHR rats yielded the same magnitude of elevations in
aldosterone, indicating a good translatability from rat to human.
Conclusions: Urinary Na
+/K
+ and plasma aldosterone appear to be translatable biomarkers of MR antagonism
following administration of single or multiple doses of compound, respectively.
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Accumulating evidence supports the role of the minera-
locorticoid receptor (MR) in the pathogenesis of various
diseases such as hypertension [1], diabetic nephropathy
[2], and cardiac fibrosis [3]. Aldosterone, the primary
endogenous ligand for MR, plays a pivotal role in the
reabsorption of Na
+ and the excretion of K
+ in various
epithelia such as the distal nephron [4] and the colon
[5]. In addition to its essential role in the regulation of
electrolyte balance, MR has been localized to numerous
non-epithelial tissues where it has been implicated in
the development of fibrosis, inflammation, and oxidative
stress [6]. Current marketed MR antagonists, such as
spironolactone and eplerenone, are mainly indicated for
the treatment of hypertension and various forms of con-
gestive heart failure. However, given the accumulating
evidence supporting a role for MR antagonists in
numerous additional diseases such as diabetic nephropa-
thy, pharmaceutical companies have expressed a
renewed interest in compounds that antagonize MR.
Newer generations of MR antagonists are now being
explored for novel indications.
To support the preclinical and clinical development of
novel MR antagonists, translatable biomarkers are
needed early in the discovery process to select com-
pounds with the greatest likelihood of achieving the
warranted efficacy in the target patient population. One
advantage for this class of compounds is the availability
of prior data generated with marketed MR antagonists,
such as eplerenone and spironolactone, that can be
leveraged to assess the translatability of biomarkers. The
challenge remains to identify animal models in which
the same biomarkers are equally robust. Animal models
of disease often do not express all the traits of the
human pathology. This is particularly true for animal
models of diabetic nephropathy [7-9]. Additionally, most
preclinical studies focus on renal histopathological
changes to demonstrate drug effects thereby hindering
translatability of their findings to humans [10,11].
Therefore, identifying and validating translatable
mechanism biomarkers for drug interventions targeting
this disease are essential.
Previous reports have indicated a measurable effect of
MR antagonists on urinary sodium to potassium ratio
(Na
+/K
+) in preclinical species, consistent with effects of
aldosterone on electrolyte balance [12-14]. Moreover,
elevations in plasma renin activity (PRA) and aldoster-
one were demonstrated in response to eplerenone treat-
ment [15,16]. Despite these elevations in components of
the renin angiotensin system, eplerenone decreased tub-
ular Na
+ reabsorption, highlighting the importance of
aldosterone in regulating electrolyte balance [15]. We
provide herein evidence for the quantitative translatabil-
ity from rats to humans of urinary Na
+/K
+ as a
mechanism biomarker for MR blockade following
administration of single doses of compounds. Further-
more, we demonstrate a time- and dose-dependent
increase in aldosterone with chronic MR blockade, and
we further highlight the translatability of this biomarker
to humans.
Methods
In vitro potency
Huh7 cells (ATCC, Manassas, VA) were transiently
transfected with a luciferase reporter gene under the
control of a Gal4 response element (Gal4-RE-luc) and a
plasmid containing the Gal4 DNA binding domain fused
to the MR ligand binding domain (Gal4-MR-LBD). Cells
were treated with a submaximal level of ligand (~EC80)
in the presence or absence of compounds, in a serum
free media. Measurement of luciferase activity allowed
for a quantitative determination of the reporter tran-
scription in the presence of competitive antagonists,
thus yielding an IC50 for these compounds.
Effect of PF-03882845 and eplerenone on urinary sodium
to potassium ratio (Na
+/K
+) in Sprague-Dawley rats
All procedures were conducted in accordance with Insti-
tutional Animal Care and Use Committee guidelines
and regulations at Pfizer Inc. (Groton, CT). Male, caro-
tid artery catheterized Sprague-Dawley rats were
received from Charles River laboratories at approxi-
mately 11 weeks of age (body weight = 300-400 g). Rats
were singly housed in wire cages on a 12-hour light
cycle and were provided standard laboratory chow diet
and water ad libitum prior to and throughout the stu-
dies. Following acclimation, animals were randomly
assigned to treatment groups (n = 6/group). In one
experiment, rats received single oral doses of 3, 10, or
30 mg/kg PF-03882845 or vehicle (0.5% methylcellulose
and 0.1% polysorbate 80) in a dosing volume of 5 mL/
kg. In a second experiment, rats received single oral
doses of 5, 30, or 300 mg/kg eplerenone or vehicle
(0.5% methylcellulose and 0.1% polysorbate 80) in a dos-
ing volume of 5 mL/kg. Blood samples were collected
via catheter at 1, 2, 4 and 7 hours post-dose for mea-
surement of plasma drug exposure. Urine samples were
collected overnight prior to dosing and at intervals of 0-
2, 2-4, and 4-7 hours post-dose for measurement of
urinary sodium and potassium concentration.
Temporal effect of PF-03882845 on plasma aldosterone in
Spontaneously Hypertensive Rats (SHR)
To determine the time course for aldosterone modula-
tion by MR antagonists, male carotid artery catheterized
SHR (11 weeks of age, body weight = 250-300 g, from
Charles River laboratories, Portage, MI) were randomly
assigned (n = 9/group) to receive 30 mg/kg PF-
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administered at 6AM, second dose administered at
4PM) or vehicle (0.5% methylcellulose and 0.1% polysor-
bate 80) for a duration of 1, 3, 5 or 7 days. Throughout
the study, rats were provided standard laboratory chow
diet and water ad libitum.O nd a y s1 ,3 ,5a n d7 ,b l o o d
samples were collected via catheter prior to dosing and
at 1, 2, 4 and 7 hours post-dose for measurement of
plasma aldosterone and drug levels. A different subset
of SHR was used for each day of the time course, in
order not to exceed the maximal allowed daily blood
collection. The rationale for utilizing the SHR strain was
to maintain consistency with additional undisclosed stu-
dies conducted in parallel with the above experiments.
SHR, like Sprague-Dawley rats, possess a functional
renin-angiotensin-aldosterone system (RAAS) [17,18].
Effect of PF-03882845 and eplerenone on plasma
aldosterone levels in SHR
To characterize the dose-response of PF-03882845 and
eplerenone on plasma aldosterone levels, male carotid
artery catheterized SHR (11 weeks of age, body weight =
250-300 g, from Charles River laboratories, Portage, MI)
were randomly assigned (n = 9/group) to receive 20, 30
or 50 mg/kg PF-03882845 twice daily (BID) by oral
gavage for 5 days, or 50, 150, or 450 mg/kg eplerenone
BID by oral gavage for 7 days. The control group was
treated with vehicle (0.5% methylcellulose and 0.1%
polysorbate 80). Throughout the study, rats were pro-
v i d e ds t a n d a r dl a b o r a t o r yc h o wd i e ta n dw a t e rad libi-
tum. On the final study day, blood and serum samples
were collected via catheter prior to dosing (6AM) and at
1, 2, 4 and 7 hours post-dose for measurement of aldos-
terone and drug levels.
Pharmacodynamic measurements in rats
Urinary sodium and potassium concentrations were
measured using a Siemens Advia 1800 chemistry analy-
zer. Plasma aldosterone levels in rats were measured
using a RIA kit from Diagnostic Systems Laboratories
(Webster, TX) with a lower limit of quantitation
(LLOQ) of 25 pg/mL. Concentrations of aldosterone in
human serum were determined using a validated LC/
MS/MS method with a LLOQ of 1 ng/dL (Quest
Diagnostics).
Determination of PF-03882845 and eplerenone in rat
plasma
Mass spectrometry was performed on a Sciex API4000
system equipped with a turbo-ionspray source (Applied
Biosystems, Foster City, CA, USA) operated in negative
ion mode for PF-03882845 and in positive ion mode for
eplerenone. High performance liquid chromatography
(HPLC) analysis was conducted on a Shimadzu 10ADvp
Binary HPLC system (Shimadzu Scientific Instruments
Columbia, MD, USA) with a CTC-PAL (Thermo Scien-
tific, Franklin, MA, USA) as the autosampler. Chroma-
tographic separations were performed by reversed-phase
gradient elution of each compound and the internal
standard on a Phenomenex Luna C18 (2) 30 × 2 mm 5
μ HPLC column (Torrance, CA, USA) using 10 mM
ammonium acetate and 1% isopropyl alcohol in water
and acetonitrile. Analyst (version 1.4.1, Applied Biosys-
tems, Foster City, CA, USA) was employed to control
the instrument operation and acquire data in multiple
reaction monitoring (MRM) mode. The ion transitions
for PF-03882845 and the internal standard were 418.2
® 374.1 and 356.1 ® 312.1, respectively. The dynamic
range of the assay was from 1 ng/mL to 10,000 ng/mL
using linear regression with a weighting of 1/x
2. The ion
transitions for eplerenone and the internal standard
were 415 ® 163.5 and 368.1 ® 112.1, respectively. The
dynamic range of the assay was from 1 ng/mL to 5,000
ng/mL, using linear regression with a weighting of 1/x
2.
Unbound plasma drug concentrations for PF-03882845
and eplerenone were determined by multiplying total
plasma concentration by the fraction of drug unbound
in rat plasma (fu = 0.0038 for PF-03882845, and fu =
0.81 for eplerenone).
Non clinical data analysis
The relationship between urinary log10 (Na
+/K
+)d a t a
and plasma concentrations of eplerenone or PF-
03882845 was described using an indirect response
model depicted in the clinical data analysis section. Data
analysis for plasma aldosterone was performed using
Graphpad Prism 5. EC50 values for each compound
were determined by fitting the log of the average drug
concentration over 0 to 7 hours (determined by area
under the curve (AUC)0-7/7) versus the aldosterone
AUC0-7 to a simple Emax model. The free drug concen-
tration required to elicit a 2-fold increase in aldosterone
was determined using the interpolation function for the
log (drug concentration) versus response curve fit. One-
way ANOVA followed by Tukey’s post- hoc analysis was
used to establish significance between the treatment
groups.
Clinical Studies
A single center, double-blind, randomized, placebo-con-
trolled, rising oral dose, sequential panel study was con-
ducted in 32 healthy male subjects (Study EE3-96-02-
004). Subjects had a mean age of 33.4 years (range 19 to
62 years) and a mean body weight of 75.1 kg (range
61.4 to 91.0 kg). Of the 32 enrolled subjects, 31 were
Caucasian and 1 was Asian. Subjects were in good gen-
eral health as determined by the Investigator in the pre-
treatment period. Subjects were excluded if they had
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inal, or endocrinologic abnormality. Every subject pro-
vided written informed consent prior to admission to
the study. Subjects were administered 100, 300 or 1000
mg of eplerenone or placebo on day 1, followed 48
hours later by the same dose administered once-a-day
for 11 consecutive days. On day 1 and after 11 days of
dosing, blood samples were drawn at 0 (pre-dose) and
0.5, 1, 2, 3, 4, 6, 8, 12, 16 and 24 hours post-dose for
determination of plasma drug concentration. Urine sam-
ples were collected at 0-2, 2-4, 4-6, 6-8, 8-12, and 12-24
hours post-dose on days 1 and 11 for determination of
electrolyte levels. A pre-dose 24 hour urine sample was
also collected from each subject on day 0. Subjects were
maintained on an in-house controlled salt diet from
three days prior to the first dose administration until
day 14. The controlled salt diet restricted subjects to a
d a i l yi n t a k eo f1 5 0m m o lo fs o d i u ma n d8 0m m o lo f
potassium.
A methodology study to evaluate the pharmacody-
n a m i c( P D )r e s p o n s eo fa1 0 0m go r a ld o s eo fe p l e r e -
none administered once daily for 10 days to healthy
volunteers was also conducted (Study A6141115).
Twenty (20) subjects (age 18 - 55 years) in the single
cohort were randomized as 15 on eplerenone and 5 on
placebo. All subjects enrolled in this study were male
with a mean age of 39.5 years in the eplerenone group
and 36.4 years in the placebo group. The mean body
weight of the subjects was 79.4 kg (range 70.0 to 101.8
kg) in the eplerenone group and 80.3 kg (range 76.4 to
86.8 kg) in the placebo group. Of the 20 enrolled sub-
jects, 18 were Caucasian and 2 were African-American.
Generally, demographic characteristics were comparable
between treatment groups. Subjects were in good gen-
eral health as determined by the Investigator in the pre-
treatment period. Subjects were excluded if they had
any history of renal, hepatic, cardiovascular, gastrointest-
inal, or endocrinologic abnormality. Every subject pro-
vided written informed consent prior to admission to
the study. Subjects were maintained on an in-house
controlled salt diet from three days prior to the first
dose of study drug until day 13 of the study. Dosing was
for 10 consecutive days; beginning on day 1, and sub-
jects received once daily oral doses of 100 mg eplere-
none or placebo. Serial blood samples were collected
from each subject on days 1 and 10 for measurement of
plasma eplerenone levels. Serum aldosterone (PD bio-
marker) levels were measured on days 0, 1 and 10 of
the study.
Determination of eplerenone concentration in human
plasma
Plasma concentrations of eplerenone in study EE3-96-
02-004 were determined using a validated LC/MS/MS
method (Phoenix International Life Sciences, Montreal,
Canada) with a LLOQ of 10 ng/mL. Plasma concentra-
tions of eplerenone in study A6141115 were determined
using a validated LC-MS/MS method with a LLOQ of
10 ng/mL (WuXi AppTec, Shanghai, China).
Clinical data analysis
Urinary log10 (Na
+/K
+) was analyzed based on measure-
ments obtained following a single dose (day 1) and mul-
tiple doses (day 11) of study drug. An indirect response
model was used to describe the relationship between the
urinary Na
+/K
+ and plasma concentrations of eplere-
none on each day:
dR
dt
= kin ∗ (1 + STIM) − kout ∗ R
STIM = PBO +
Emax∗Conc
EC50 + Conc
where R = urinary Na
+/K
+, kin = appearance rate con-
stant, kout = removal rate constant, STIM = drug effect,
Conc = average plasma concentration of eplerenone
during the collection interval, PBO = placebo response,
Emax = maximal eplerenone stimulatory effect and EC50
= concentration producing 50% half-maximal stimula-
tion. Modeling was performed using nonlinear mixed
effects modeling methodology as implemented in the
NONMEM software system, version VI level 1.2 (Globo-
Max LLC, Hanover, MD).
To evaluate the aldosterone (PD biomarker) response
to 100 mg eplerenone, the area under the effect curve
from time 0 to 24 hours area under the effective curve
(AUEC [0 24]), was calculated for serum aldosterone for
each subject and day using the linear trapezoidal
method. Baseline values were defined as the AUEC
values on day 0. In addition, the linear mixed effect
repeated measures models were used to analyze the nat-
ural log transformed AUEC with treatment, day and
treatment by day interaction as fixed effects, natural log
transformed AUEC day 0 value as covariate, and subject
as a random effect. The adjusted mean differences and
90% confidence intervals (CI) for the differences were
obtained from the model and exponentiated to provide
estimates of the ratio of adjusted geometric means and
90% CI for the ratios of each treatment.
Results
Functional potency of mineralocorticoid receptor
antagonists
PF-03882845 potently antagonized MR with a geometric
mean IC50 of 0.75 nM (90% CI: 0.504-1.11; n = 6) in
Huh7 cells transiently transfected with MR-LBD, in a
serum free media. Similarly, eplerenone antagonized MR
with an IC50 of 109 nM (90% CI: 79.3-150; n = 6).
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+/K
+
To determine the effects of MR antagonists on electro-
lytes, urinary Na
+/K
+ was measured following a single
oral administration of 3, 10 or 30 mg/kg PF-03882845
or 5, 30 or 100 mg/kg eplerenone to Sprague-Dawley
rats. Both eplerenone and PF-03882845 resulted in an
increase in urinary Na
+/K
+ over 7 hours that was con-
centration-dependent (Figure 1). Longitudinal models
incorporating no drug effect (placebo/vehicle), linear
drug effect or an Emax drug effect were evaluated for
eplerenone and/or PF-03882845 preclinical and clinical
data. Model selection was performed based on standard
diagnostic plots and the comparison of objective func-
tion values using the likelihood-ratio test [19,20]. The
longitudinal model with an Emax drug effect when com-
pared to a model with no drug effect resulted in a p-
value < 0.001 indicating the superiority of a concentra-
tion-dependent Emax model for describing the data.
Diagnostic plots supported the likelihood ratio test for
model selection.
Consistent with differences in in vitro potency
between the two compounds, the estimated free EC50 of
eplerenone and PF-03882845 from the indirect response
model were 460 nM and 1.90 nM, respectively. When
eplerenone was administered for a duration of 7 days,
effects on urinary Na
+/K
+ were no longer apparent.
Similarly, effects on urinary Na
+/K
+ following 3 days of
dosing with PF-03882845 were attenuated compared to
effects observed after a single dose (data not shown).
In humans, eplerenone elicited an increase in urinary
Na
+/K
+ ratio following administration of single oral
doses of 100, 300 or 1000 mg (Figure 2). In this study,
eplerenone was well tolerated during single- and multi-
ple-dose administration. There were no clinically signifi-
cant changes in physical examinations, vital signs
(including blood pressure), ECG, or clinical laboratory
tests (including serum potassium, sodium levels and
renal function). Consistent with preclinical findings,
effects of eplerenone in healthy humans were concentra-
tion-dependent. The estimated EC50 for the effect of
eplerenone on urinary Na
+/K
+ was 557 nM, demonstrat-
ing a strong translatability from rats to humans. More-
over, the effect of eplerenone on urinary Na
+/K
+ ratio
was not sustained with chronic dosing (data not shown).
The effect of PF-03882845 on urinary Na
+/K
+ has not
yet been studied in humans.
Effect of MR antagonists on plasma aldosterone
To characterize the time-course of MR antagonism on
aldosterone changes, plasma aldosterone levels were
measured following a single (1 day) and multiple admin-
istration (BID for 3, 5 or 7 days) of 30 mg/kg PF-
03882845 to SHR. Results indicated a time-dependent
increase in aldosterone levels up to 5 days of BID dosing
(Figure 3). A maximal effect was reached by day 5 for
this compound, as day 7 levels did not differ from day 5
despite a continued increase of the drug concentration
(average concentration on day 5 was 23.2 nM, average
concentration on day 7 was 67.0 nM). These results
indicate that chronic dosing is warranted in order to
achieve a maximal effect on aldosterone.
To characterize the dose-response of eplerenone and
PF-03882845 on plasma aldosterone levels, SHR were
treated with either PF-03882845 at doses of 20, 30 and
50 mg/kg for 5 days, or eplerenone at doses of 50, 150,
or 450 mg/kg for 7 days, or vehicle (0.5% methylcellu-
lose and 0.1% polysorbate 80). Treatment with eplere-
none resulted in a dose-responsive increase in
aldosterone with an EC50 of 764 nM (Figure 4A). PF-
03882845 elicited an increase in aldosterone that was
sustained over 7 hours post-dose, with an EC50 of 3.08
nM (Figure 4B). These potencies are within 2-fold of
that determined from the concentration effect curves on
urinary Na
+/K
+ ratio.
The effect of eplerenone on serum aldosterone in
humans was assessed at a dose of 100 mg administered
once daily for 10 consecutive days in healthy volunteers.
In this study, treatment with eplerenone was safe and
well-tolerated. There were no clinically significant
changes from baseline for any hematology, clinical
chemistry (including serum potassium or sodium levels),
or urinalysis test values. In addition, there were no
changes in vital sign parameters from baseline (includ-
i n gb l o o dp r e s s u r e )t h a tw e r e assessed as clinically sig-
nificant. Following 10 days of eplerenone or placebo
administration, serum aldosterone AUC was calculated
and normalized to serum aldosterone AUC at baseline
(day 0). The dose of 100 mg eplerenone resulted in a
2.2-fold increase in aldosterone day 10 AUC/day 0 AUC
versus placebo with an average unbound plasma drug
concentration of 491 nM, as measured on day 10 of
dosing. In comparison, an average eplerenone unbound
plasma concentration of 514 nM in rats resulted in a
2.2-fold increase in aldosterone versus vehicle, when
eplerenone was administered for 7 days. These results
indicate a high translatability for aldosterone modulation
by MR antagonists from rat to human.
Discussion
We studied the effect of MR blockade on urinary Na
+/K
+
and aldosterone. Our findings demonstrate the translat-
ability of urinary Na
+/K
+ from rat to human as a
mechanism biomarker for acute effects of MR antagon-
ism. Moreover our results indicate that aldosterone is a
translatable mechanism biomarker following chronic
administration of MR antagonists. These findings are of
crucial importance for the clinical development of novel
MR antagonists.
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Figure 1 Effect of eplerenone and PF-03882845 on urinary Na
+/K
+ in rats. Eplerenone (A) and PF-03882845 (B) elicited a dose-dependent
increase in urinary Na
+/K
+ ratio in Sprague-Dawley rats following administration of single doses. Points represent observed effects in individual
rats. The solid line represents the predicted time course of the effect derived from the indirect response model described in the methods
section.
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+/K
+ in humans. Eplerenone elicited a dose-dependent increase in urinary Na+/K+ in
humans. Points represent observed effect in individual subjects. The solid line represents the predicted time course of the effect derived from
the indirect response model described in the methods section.
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Figure 3 Time-dependent effects of PF-03882845 on plasma aldosterone AUC. PF-03882845 resulted in a time-dependent increase in
plasma aldosterone AUC corrected to vehicle in Spontaneously Hypertensive Rats (SHR). Statistical analysis indicated an overall significant effect
of time (P = 0.0454 by one-way ANOVA). There was no significance between any two groups when analyzed with Tukey’s Multiple Comparison
Test. Data are shown as mean + SEM.
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Figure 4 Effect of chronic administration of eplerenone and PF-03882845 on plasma aldosterone. Treatment of Spontaneously
Hypertensive Rats (SHR) with eplerenone for 7 days caused significant increases in plasma aldosterone (A) yielding a calculated EC50 of 764 nM.
Treatment with PF-03882845 for 5 days resulted in significant elevations in aldosterone (B) and yielded an EC50 of 3.08 nM. All data are
represented as mean + SEM. In Figure A,* and ^ indicate a significant difference from vehicle and 450 mg/kg BID, respectively. In Figure B, * and
^ indicate a significant difference from vehicle and 50 mg/kg BID, respectively.
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MR, regulates sodium balance by increasing the expres-
sion of the epithelial Na
+ channel (ENaC) [21] and the
Na
+/K
+-ATPase pump found respectively on the apical
and the basolateral membrane of the distal epithelial
cells. These increases are at least partially driven
through effects on the sodium/glucocorticoid kinase 1
(SGK1) which has been shown to be strongly induced
by aldosterone. In turn, SGK1 has been demonstrated to
phosphorylate the ubiquitin-ligase Nedd4-2 [22,23],
thereby impairing its ability to degrade ENaC. The net
effect is an increase in ENaC pool at the apical mem-
brane. In accordance with the crucial role of aldosterone
in salt reabsorption, MR blockade elicited an increase in
urinary Na
+/K
+ in rats and humans, in a dose-depen-
dent manner. Importantly, the potency of eplerenone in
this assay was highly translatable from rat to human,
supporting the use of urinary Na
+/K
+ in rats to enable
dose selection for clinical trials.
Interestingly, increases in urinary Na
+/K
+ were not
sustained with chronic dosing in rats treated with epler-
enone or PF-03882845. Although the reason for this
loss of effect is not clearly understood, potential com-
pensatory mechanisms could account for this finding.
As shown in our study and in previous reports
[15,16,24,25], MR antagonism is associated with a feed-
back increase in PRA (see Additional File 1), and there-
fore angiotensin II (AngII). The latter has been
demonstrated to exert direct effects through the angio-
tensin type 1 (AT1) receptor on sodium channels [26].
Indeed, Beutler et al. revealed a decrease in a-ENaC
protein and mRNA abundance in response to AT1
receptor blockade in Na
+Cl
- restricted rats [27]. Impor-
tantly, this effect was not altered by spironolactone
administration suggesting a direct regulation of a-ENaC
by AngII, independent of aldosterone and MR. Other
regulators of salt and water balance include vasopressin
[28] which has been shown to result in an increase in
a-, b-a n dg-ENaC subunits in the rat renal collecting
duct with chronic infusion [29,30]. This effect appears
to be largely driven through translational regulations.
Glucocorticoids have also been shown to stimulate renal
sodium reabsorption through effects on several trans-
porters, namely the sodium-hydrogen exchange by Na
+/H
+ exchanger 3 in the proximal tubule [31], the Na-
K-Cl cotransporter (NKCC 2) in the thick limb of Henle
[32], the Na-Cl cotransporter (NCC) in the distal tubule
[32,33], and ENaC in the connecting tubule and collect-
ing ducts [34]. Indeed, early on, Stanton demonstrated
that chronic infusion with dexamethasone in adrenalec-
tomized rats increased sodium reabsorption, albeit to a
lesser extent than physiological levels of aldosterone
[35]. Thus, it is possible that compensatory increases in
either glucocorticoids or vasopressin may offset the
chronic effect of MR antagonists on urinary Na
+/K
+.
However, in the absence of evidence supporting the
above hypotheses, our data only support a role for PRA
and therefore AngII in eliciting these compensatory
responses but does not preclude a role for additional
culprits such as vasopressin or glucocorticoids. Since
clinical and preclinical data indicate a loss of effect on
urinary Na
+/K
+ following chronic treatment with eplere-
none; thereby precluding the use of this biomarker in
chronic studies, we investigated changes in aldosterone
in rats and humans as a mechanism biomarker of
chronic MR antagonism.
In the present experiments, MR antagonists induced
an increase in serum aldosterone levels. These findings
are concordant with previous reports. Menard et al,
reported an increase in plasma aldosterone after two
weeks of spironolactone treatment in SHR on high salt-
normal potassium diet [36]. This has been confirmed in
normal rats treated chronically with eplerenone [37].
L i k e w i s e ,D eP a u l a ,e ta lr e p o r t e da ni n c r e a s ei nb o t h
PRA and aldosterone after eplerenone treatment for 10
days in lean dogs [15]. Similarly, in humans, eplerenone
resulted in elevations in serum aldosterone (65%) and
plasma active renin (94%) when administered for 8-
weeks in addition to a fixed-dose of an angiotensin con-
verting enzyme (ACE) inhibitor or angiotensin receptor
blocker (ARB) in mildly hypertensive patients [16]. In a
larger study, Weinberger et al. reported an increase in
serum aldosterone with eplerenone treatment that was
dose-responsive [38]. In patients with resistant hyperten-
sion, Calhoun et al. showed an inverse correlation
between blood pressure and serum aldosterone after
treatment with eplerenone for 12 weeks [39]. We
expand on these findings by demonstrating translatabil-
ity of this biomarker from rat to human.
Further, we demonstrate a time-dependent increase in
aldosterone with MR antagonism, as maximum levels of
circulating aldosterone were not reached until day 5
with PF-03882845 despite an increase in drug exposure
levels. This delay in achieving the maximal response is
likely a result of a feedback mechanism to offset the loss
of MR-mediated aldosterone effects. AngII and K
+ have
been shown to be the main physiological regulators of
aldosterone synthase [40], increasing mRNA levels of
the enzyme in a time and concentration dependent
manner [41]. Thus, increases in PRA and AngII ensuing
from a decreased Na
+ reabsorption in the proximal
tubules, would lead to an up-regulation of aldosterone
synthase, and consequently increases in aldosterone.
Mechanisms independent of AngII may also be driving
the rise in aldosterone. This is supported by the absence
of correlation between aldosterone and AngII levels in
congestive heart failure patients treated with an ACE
inhibitor, in which elevations in aldosterone were not
Eudy et al. Journal of Translational Medicine 2011, 9:180
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Another potential explanation for the increase in aldos-
terone is a direct regulation of aldosterone synthase by
MR. However this seems unlikely given the absence of a
mineralocorticoid/glucocorticoid response element on
the gene encoding for this enzyme in humans without
familial hyperaldosteroneism-1 [43]. Nonetheless, the
presence of MR in the adrenals [44] could lead to an
indirect regulation of aldosterone synthase expression.
Further studies are warranted to fully understand the
mechanisms underlying the rise in aldosterone following
MR antagonism.
Conclusions
Urinary Na
+/K
+ measured in rats constitutes a valid
quantitative mechanism biomarker of MR antagonism,
as it correlates with the in vitro IC50 of the compounds
tested. Importantly, this biomarker appears to be trans-
latable to humans, as evidenced by clinical data gener-
ated with eplerenone. Aldosterone measurements in rats
following treatment with MR antagonists yielded similar
potencies to those calculated from effects on urinary Na
+/K
+. Furthermore, the same magnitude of aldosterone
elevations were observed in rats and humans at similar
unbound concentrations of eplerenone, thereby indicat-
ing translatability of this biomarker from rat to human.
Taken together, our findings support the use of urinary
Na
+/K
+ as a translatable biomarker of MR antagonism
in single dose studies. Moreover, our results support the
use of aldosterone as a translatable biomarker of chronic
MR blockade.
Additional material
Additional file 1: Effect of chronic administration of PF-03882845
on plasma renin activity. Treatment of Spontaneously Hypertensive
Rats (SHR) with PF-03882845 for 7 days caused significant increases in
plasma renin activity (PRA) at the dose of 50 mg/kg BID. * and ^ indicate
significantly different from vehicle and 50 mg/kg BID, respectively. Data
are depicted as mean + SEM (n = 9). Statistical analysis was performed
using ANOVA followed by Tukey’s post-hoc test.
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